Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
AstraZeneca
Teva
Mallinckrodt
Farmers Insurance
McKesson
Daiichi Sankyo
US Army
Federal Trade Commission

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,003,673

« Back to Dashboard

Which drugs does patent 8,003,673 protect, and when does it expire?

Patent 8,003,673 protects CUBICIN and is included in one NDA.

This patent has three patent family members in three countries.
Summary for Patent: 8,003,673
Title:Daptomycin for the treatment of biofilm and catheter salvage
Abstract: Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or catheter salvage involving daptomycin. Particular formulations include daptomycin in lactated Ringer's solution having a rapid kill curve against the bacteria of the biofilm.
Inventor(s): Alder; Jeffrey (Harvard, MA), Silverman; Jared (Brookline, MA), Mortin; Lawrence (Framingham, MA), Van Praagh; Andrew (Chelmsford, MA)
Assignee: Cubist Pharmaceuticals, Inc. (Lexington, MA)
Application Number:11/916,089
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;

Drugs Protected by US Patent 8,003,673

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 AP RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,003,673

PCT Information
PCT FiledMay 31, 2006PCT Application Number:PCT/US2006/021006
PCT Publication Date:December 07, 2006PCT Publication Number: WO2006/130629

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Queensland Health
Moodys
Chinese Patent Office
Boehringer Ingelheim
Teva
Citi
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.